Ghafouri Ali, Movafegh Ali, Nasr-Esfahani Mehran, Gholamrezanezhad Ali, Madhkhan Sepide
Department of General and Thoracic Surgery, Shariati Teaching Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Middle East J Anaesthesiol. 2008 Feb;19(4):767-80.
In a prospective, observer-blind study, 50 patients scheduled for posterolateral thoracotomy were investigated to compare the effects of intermittent intercostal extrapleural bupivacaine (n = 25) and intravenous pethidine (n = 25) on post-thoracotomy pain and pulmonary function. The severity of chest pain (objectified by the use 5-point scale of Prince Henry) and changes in spirometric values [forced vital capacity (FVC), forced expired volume in 1 s (FEV1) and FEV1/FVC] were monitored during the first three postoperative days. Because intravenous pethidine was used to supplement pain relief in the patients who received intercostal analgesia, total pethidine used was compared to that administered to patients in the intravenous pethidine group.
There were no statistical significant differences regarding patient demographics in both groups. No complications occurred. There was no significant difference between mean pain scores in the first postoperative day, but in the second and third postoperative days and also in the whole first 72 post-operative hours, pain scores were significantly higher in the intravenous group than the intercostal group. The postoperative decrease in FVC and FEV1 was significantly less with intercostal bupivacaine compared with the intravenous pethidine. There was no significant intergroup difference in the post- to pre-operative FEV1/FVC ratio. The total amount of the pethidine received by the patients was significantly higher in the intravenous group than the intercostal group.
Intermittent intercostal nerve block with bupivacaine appears to be a promising, safe and reliable technique in the management of post-thoracotomy pain. Use of intercostal bupivacaine could significantly reduce or even eliminate the postoperative need for systemic narcotics.
在一项前瞻性、观察者盲法研究中,对50例行后外侧开胸手术的患者进行调查,以比较肋间胸膜外间断注射布比卡因(n = 25)和静脉注射哌替啶(n = 25)对开胸术后疼痛和肺功能的影响。在术后的前三天监测胸痛的严重程度(采用亨利王子5分制进行客观评估)以及肺功能测定值的变化[用力肺活量(FVC)、第1秒用力呼气量(FEV1)和FEV1/FVC]。由于静脉注射哌替啶用于补充接受肋间镇痛患者的疼痛缓解,因此将使用的哌替啶总量与静脉注射哌替啶组患者使用的量进行比较。
两组患者的人口统计学特征无统计学显著差异。未发生并发症。术后第一天平均疼痛评分无显著差异,但在术后第二天和第三天以及整个术后的前72小时,静脉注射组的疼痛评分显著高于肋间组。与静脉注射哌替啶相比,肋间注射布比卡因术后FVC和FEV1的下降明显较少。术前和术后FEV1/FVC比值组间无显著差异。静脉注射组患者接受的哌替啶总量显著高于肋间组。
布比卡因间断肋间神经阻滞似乎是一种有前景、安全且可靠的开胸术后疼痛管理技术。使用肋间布比卡因可显著减少甚至消除术后对全身性麻醉剂的需求。